
|Videos|September 28, 2018
Later Lines of Therapy for Metastatic Colorectal Cancer
Advertisement
Episodes in this series

Transcript:
Tanios Bekaii-Saab, MD: Almost 90% or more of patients who progressed through first-line therapy will make it to the second line. Second-line options will depend on what you
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient mHSPC
2
FDA Approves Adjuvant Belzutifan Plus Pembrolizumab in ccRCC
3
Subgroup Analyses Confirm Clinically Meaningful Revumenib Responses in AML Across Mutational Profiles
4
Data Support Luspatercept at Maximum-Approved Dose for Transfusion-Dependent Lower-Risk MDS
5

















































































